ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1648

In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells

Giulia Frazzei1, Ana Merino Vico2, Jan Piet van Hamburg2, Ronald Van Vollenhoven3 and Sander Tas4, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), B-Lymphocyte, rheumatoid arthritis

Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells may further clarify their role in RA. NF-κB signaling is a key regulator of B cell responses, including proliferation, differentiation, and (auto)antibody production, making NF-κB a prime candidate to target ACPApos B cells. Because the frequencies of ACPApos B cells in the peripheral blood of RA patients are low, we optimized an expansion assay for memory B cells, to study whether NF-κB inhibition is effective in targeting functional (autoreactive) responses.

Methods: Memory B cells from healthy donors and ACPApos B cells from RA patients were sorted and cultured with CD40L, 50 ng/ml IL-2, 10 ng/ml IL-21, and 10 ng/ml BAFF. ACPApos B cell clones were cultured with 2.25 µg/ml anti-CD40 and 1 ng/ml IL-21. Plasma cells differentiated from expanded memory B cells were culture with 200 ng/ml APRIL and 10 ng/ml IL-6. Canonical and non-canonical NF-κB signaling were targeted by validated small molecule inhibitors targeting Inhibitor of κB kinase β (IKKβ) and NF-κB inducing kinase (NIK), respectively. B cell responses were evaluated by flow cytometry, and antibody production was measured by ELISA.

Results: Memory B cells were expanded from 250 cells/well and differentiated into plasma cells in vitro for 8 days (mean ± SEM B cells: n=29.4×103±2.7×103; plasma cells: n=3.3×103±0.35×103); survival was analyzed at day 16 (mean ± SEM B cells: n=3.3×103±1.1×103; plasma cells: n=1.4×103±0.46×103). Both NIK (2.5 µM) and IKKβ (1.0 µM) inhibition resulted in a significant decrease in B cell expansion (NIKi=74.6%; IKKβi=63.1%) and plasma cell differentiation (NIKi=78.1%; IKKβi=45.7%) at day 8, with stronger effect of NIKi. At later timepoint, treatment of plasma cells with NF-κB inhibitors did not have a significant effect on plasma cell number (mean ± SEM DMSO=3.9×103±1.5×103; NIKi=3.2×103±1.1×103; IKKβi=2.8×103±1.2×103), although NIKi resulted in significant decreased survival (DMSO=83.2%; NIKi=77.6%). In ACPApos B cell clones from RA patients treated with these agents (12.5-50.0 µM) upon anti-CD40L and IL-21 stimulation, we observed a dose-dependent reduction in proliferation and IgG production. In addition, we succeeded in isolating ACPApos and ACPAneg B cells from the peripheral blood of RA patients, and quantify ACPA production. At present the above results are being corroborated in freshly isolated ACPApos B lineage cells from RA patients.

Conclusion: Our data point towards a critical role of the NF-κB signaling pathways in the functional responses of ACPA-producing B cells. Consequently, targeting NF-κB signaling may have beneficial effects in limiting (autoreactive) B cell responses in RA and potentially other immune-mediated inflammatory disorders driven by B cells.


Disclosures: G. Frazzei: None; A. Merino Vico: None; J. van Hamburg: None; R. Van Vollenhoven: AbbVie, 2, 6, AstraZeneca, 2, Biogen, 2, Biotest, 2, Bristol Myers Squibb, 5, Celgene, 2, Eli Lilly, 5, Galapagos, 2, 6, Gilead, 2, GSK, 5, Janssen, 2, 6, Pfizer, 2, 6, 12, Support for educational programs, Roche, 12, Support for educational programs, Servier, 2, UCB, 2, 5, 6; S. Tas: None.

To cite this abstract in AMA style:

Frazzei G, Merino Vico A, van Hamburg J, Van Vollenhoven R, Tas S. In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/in-vitro-expansion-of-acpa-positive-b-cells-from-rheumatoid-arthritis-patients-and-effect-of-small-molecule-nf-%ce%bab-inhibitors-on-differentiation-and-survival-of-autoreactive-memory-b-cells-into/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vitro-expansion-of-acpa-positive-b-cells-from-rheumatoid-arthritis-patients-and-effect-of-small-molecule-nf-%ce%bab-inhibitors-on-differentiation-and-survival-of-autoreactive-memory-b-cells-into/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology